Author

H.-J. Wu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1 Cell Biology· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Approach:genetic perturbation / CRISPR· 2 Assay:CRISPR screen· 1 Approach:deep learning· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

L. Yu· 2 shared T. Fei· 2 shared W.-J. Jiang· 2 shared X. Wang· 2 shared Y. Yao· 2 shared Z. Li· 2 shared A. A. Cohen· 1 shared A. P. West· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

L. Yu

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer

C. Zhong, W.-J. Jiang, Y. Yao, Z. Li, Y. Li, S. Wang, X. Wang, W. Zhu, S. Wu, J. Wang, S. Fan, S. Ma, Y. Liu, H. Zhang, W. Zhao, , T. Fei

This study identifies convergent therapeutic targets for chemoresistance in cancer using CRISPR screens across multiple drug conditions and cancer models.

bioRxiv · Apr 24, 2024Cancer Biology

A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism

Y. Yao, Y. Zhang, Z. Li, Z. Chen, X. Wang, Z. Li, L. Yu, X. Cheng, W. Li, W.-J. Jiang, H.-J. Wu, Z. Feng, J. Sun, T. Fei

This study uses deep learning to screen FDA-approved drugs and TCM compounds for anti-SARS-CoV-2 activity by targeting cell entry, identifying several effective candidates.

bioRxiv · Jun 3, 2023Microbiology

Advancing Glycan Analysis: A New Platform Integrating SERS, Boronic Acids, and Machine Learning Algorithms

Q. Hu, D. Kuai, H. Park, H. Clark, P. B. Balbuena, J. S.-I. Kwon, H.-J. Wu

This paper introduces a glycan detection platform combining SERS, boronic acids, and machine learning to identify and quantify glycans with high accuracy.

bioRxiv · Feb 3, 2023Bioengineering

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

A. A. Cohen, P. N. P. Gnanapragasam, Y. E. Lee, S. Ou, L. M. Kakutani, J. R. Keeffe, C. O. Barnes, H.-J. Wu, M. Howarth, A. P. West, M. C. Nussenzweig, P. J. Bjorkman

The paper demonstrates that mosaic nanoparticles displaying multiple coronavirus RBDs induce cross-reactive and neutralizing antibodies against SARS-CoV-2 and zoonotic coronaviruses in mice.

bioRxiv · Nov 17, 2020Immunology

A simple and highly efficient method for multi-allelic CRISPR-Cas9 editing in primary cell cultures

P. Hoellerbauer, M. Kufeld, S. Arora, H.-J. Wu, H. Feldman, P. PADDISON

This paper introduces an optimized CRISPR-Cas9 method for efficient gene knockout and genomic deletion in primary cells, achieving >90% indel formation in 3 days.

bioRxiv · Jul 1, 2020Cell Biology